Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002–2022)

BACKGROUND & AIMS: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to non-significant, is a metric to evaluate the robustness of randomized controlled trials (RCTs). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidali, Sabrina, Sritharan, Nanthara, Campani, Claudia, Gregory, Jules, Durand, François, Ganne-Carrié, Nathalie, Ronot, Maxime, Lévy, Vincent, Nault, Jean-Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326696/
https://www.ncbi.nlm.nih.gov/pubmed/37425214
http://dx.doi.org/10.1016/j.jhepr.2023.100755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326696/
https://www.ncbi.nlm.nih.gov/pubmed/37425214
http://dx.doi.org/10.1016/j.jhepr.2023.100755

Ejemplares similares